Featured Slider

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for October 2023.

EAN Scientific Committee Chair, Thomas Berger on the forthcoming Mangement Group elections, new guidelines, and the EAN's readiness to support EU Horizon applications.

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for September 2023.

EAN President Paul Boon looks back at the 9th Congress of the European Academy of Neurology, which took place in Budapest on 1-4- July.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2023.

Four distinguished neurologists delivered the prestigious named lectures during the Presidential Symposium, held on the second day of EAN 2023.

The European Academy of Neurology (EAN) is a young society ready for the future, according to its president Prof. Paul Boon, who delivered his welcome address in the Opening Session on the first day of EAN 2023

Leading neurologists discussed how to promote brain health and overcome the global burden of brain disorders in a dedicated Studio Session on the first day of EAN 2023.

Programme Committee Chair, Ulf Kallweit, provides a preview of the 9th Annual Congress of the European Academy of Neurology, in Budapest on 1-4 July.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for June 2023.

EAN Scientific Committee Chair, Thomas Berger, reports on the new Cost-Conscious Healthcare project, the EAN Science School, and how EAN members can play a part in setting the EAN's scientific course.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.